Dr. Moore joined Zymeworks in July 2022 and currently serves as our Chief Scientific Officer. Dr. Moore brings over 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Before joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera where he oversaw research efforts to develop novel antibody-based therapeutics. Dr. Moore began his career at Human Genome Sciences (HGS), holding several titles within research culminating in Director of Lead Product Development, where he managed various genomic-based target discovery programs including efforts that led to the discovery, development, approval, and commercialization of Benlysta (belimumab) for the treatment of systemic lupus erythematosus. Dr. Moore received a PhD in molecular genetics from the University of Glasgow, performed post-doctoral work at the Roche Institute of Molecular Biology in Nutley, New Jersey, and also holds a degree in Biotechnology from the University of Strathclyde. He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.

Ms. Patterson joined Zymeworks in September 2024 and currently serves as our Executive Vice President, Chief Business Officer and Chief Financial Officer based at our Redwood City office in California. Ms. Patterson previously served as Chief Financial and Business Officer at Tenaya Therapeutics where she led corporate finance, investor relations, corporate communications, strategy and business development teams as well as other operational functions. Prior to Tenaya, she held leadership positions at Adverum Biotechnologies including Chief Financial Officer, President, Chief Executive Officer and Director. She also has held senior finance positions at Diadexus, Transcept, Exelixis, Novartis, and Chiron. Earlier in her career she worked in the audit practice of KPMG. Ms. Patterson currently serves on the board of directors of Nkarta, Inc. and Oxford Biomedica, both publicly-held companies. She earned a B.S. in business administration and accounting from Chapman University and an executive MBA from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status).

Dr. Smith joined Zymeworks in January 2023 and currently serves as our Executive Vice President and Chief Medical Officer based at our European hub in Dublin, Ireland. Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc (founded 2004). Dr. Smith received his MB BS and MD from the University of London, UK and is a Fellow of the Royal College of Physicians in London.

Mr. Dex joined Zymeworks in September 2017, and currently serves as our Senior Vice President, Corporate Secretary and General Counsel. Mr. Dex brings over 25 years of diverse legal experience to Zymeworks, having worked in private practice at prominent law firms in both the U.S. and Canada, in-house with Avigilon Corporation (a Motorola Solutions company) and the New York Public Library, and with the U.S. federal district court for the Eastern District of Pennsylvania. Mr. Dex received a J.D. from the University of Pennsylvania Law School and a B.A. from Brown University. He is a member of the bars of both New York and British Columbia.

Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Head of Technical and Manufacturing Operations. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.

Dr. Fann joins Zymeworks with more than 20 years of experience in bioprocess development and biologics manufacturing and controls. Dr. Fann started his postdoctoral career with StemCell Technologies in Vancouver, then joined Seattle Genetics in its early years. After establishing the upstream function and accomplishing the first technology transfer and clinical manufacturing for Seagen, Dr. Fann joined AbbVie Bioresearch Center. He held several leadership positions in Process Sciences and MS&T. At AbbVie, Dr. Fann experienced many clinical projects and helped to launch and scale up several commercial biotherapeutics, including the blockbuster drug Humira. Dr. Fann joined Bristol Myers Squib after returning to Seattle, as the head of M&ST and Bioprocess Development. He was leading microbial process development at BMS and accomplished several early and late-stage clinical projects. Prior to Zymeworks, Dr. Fann was VP of Bioprocess R&D at AGC Biologics, leading the global new technology development at AGC. Dr. Fann holds a PhD in Chemical Engineering from the University of British Columbia.

Ms. Desai joined Zymeworks in May 2020 and currently serves as the Vice President, Finance & Strategy. Ms. Desai brings more than 17 years of experience providing oversight of operational and strategic finance support in the customer service, technology, and life sciences industries. Prior to joining Zymeworks, Ms. Desai held a variety of R&D and Commercial FP&A and Corporate Strategy positions, starting with CTI BioPharma, Juno Therapeutics, and Alder BioPharmaceutical Inc. Ms. Desai holds her MBA with a concentration in Finance from Texas A&M University, and is an active member of Healthcare Businesswomen’s Association (HBA) Seattle Chapter holding the position of Mentoring Chair.

Mr. Donigian joined the Business Development group at Zymeworks in March 2020 and has been serving as Vice President, Business & Commercial Development since January 2024. Mr. Donigian has over 15 years in the biotechnology and biopharma industry across drug development and diagnostics. Prior to joining Zymeworks, Mr. Donigian was the Director of Business Development and BioPharma collaborations at NanoString Technologies, where he lead diagnostics business development efforts. Prior to that, Mr. Donigian was a Corporate Development consultant with Dendreon where he facilitated buy and sell side M&A analysis for late-stage opportunities. Mr. Donigian started his career developing novel cancer stem cell therapeutics at OncoMed Pharmaceuticals helping to bring multiple therapeutic candidates into first in human trials. Mr. Donigian received his Molecular Biology and Organic Chemistry from San Jose State University and an MBA from the University of Washington.

Dr. Foulkes joined Zymeworks in January 2024, bringing over 25 years of experience in the biotechnology, biopharma and medical device industries. Prior to joining Zymeworks, Dr. Foulkes was Chief Operating Officer of Arecor, a UK AIM-listed, clinical-stage biopharmaceutical company. Joining at the point of IPO, she implemented organizational and operational changes to position the company for future growth. Dr. Foulkes has held senior commercial roles covering corporate and business development, marketing and clinical portfolio management, with a therapeutic focus on immunology, inflammation, oncology and rare diseases. She has worked for organizations including Liminal Biosciences (previously known as Prometic Life Sciences), Acambis, and Cangene Corporation, and she was part of the start-up team for the medical device company, Nexan Ltd. Dr. Foulkes started her commercial career in management consultancy with McKinsey & Company and during her career she has also worked as a freelance consultant providing business development, strategy and market analysis support within the biotechnology industry, with a focus on oncology and immunology companies. Dr. Foulkes holds a PhD in Leukaemia Research and a BSc in Immunology, awarded by the University of Glasgow.

Ms. Graham joined Zymeworks in September 2018, and currently serves as our Vice President, Legal. Ms. Graham brings over 17 years of diverse legal experience to Zymeworks, having previously worked in private practice for over a decade at one of Canada’s largest law firms, and in-house with Avigilon Corporation (a Motorola Solutions company). Ms. Graham received a LL.B/J.D. from Queen’s University and a Bachelor of Arts from Concordia University. She is a member of the bar in British Columbia.

Ms. O’Connor joined Zymeworks in 2020 and currently serves as our Vice President, Human Resources & DEI. Ms. O’Connor brings more than 20 years of experience within Human Resources, specializing in the pharmaceutical and biotech industry for over 13 years. Prior to joining Zymeworks, Ms. O’Connor held a variety of Human Resources leadership positions, starting with PointClickCare, Takeda Canada, Ferring Pharmaceuticals and most recently Merz Pharma. Ms. O’Connor holds a Bachelor of Arts degree in Psychology from the University of Waterloo and a certificate in Strategic Human Resources Management from the Rotman School of Business.

Ms. Schaeffler joined Zymeworks in January 2024, bringing over 27 years of experience in the biotechnology and biopharma industries. Prior to joining Zymeworks, Ms. Schaeffler was Vice President of Clinical Operations at Syndax Pharmaceuticals, a clinical-stage oncology company developing first-in-class therapies for acute leukemias and chronic graft-versus host disease. Ms. Schaeffler has held senior roles covering clinical development and operations, leading departments and project development teams through all phases of clinical trials, culminating in regulatory filings and drug approvals. She has worked for organisations including Lundbeck, Alder Biopharmaceuticals (acquired by Lundeck), Poniard Pharmaceuticals (formerly NeoRx, Corporation), Pathogenesis and Chiron (acquired by Novartis) and PATH. Ms. Schaeffler holds an MBA and a bachelor’s degree in Bacteriology from the University of California.

Dr. Woolery joined Zymeworks in September 2019 and currently serves as our Vice President, Early-Stage Development in the Americas and Global Lead for zanidatamab zovodotin (ZW49). Dr. Woolery previously held positions at Seagen working on registrational studies with Adcetris in Peripheral T-Cell Lymphoma and Tukysa in HER2+ Metastatic Breast Cancer. Prior to transitioning to the pharmaceutical industry, Dr. Woolery practiced as a Clinical Oncology Pharmacist at the University of Texas M.D. Anderson and Banner M.D. Anderson Cancer Centers. Dr. Woolery received a PharmD from the University of Missouri-Kansas City. He also completed residency’s in clinical pharmacy practice at The University of Arizona and oncology fellowship at H. Lee Moffitt Cancer Center and Research Institute. Dr. Woolery is a board certified oncology pharmacist and a member of the American Society of Clinical Oncology and the European Society of Medical Oncology.